Trials / Available
AvailableNCT04777734
Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Pre-Approval Access for Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The aim of the Pre-Approval Access program is to provide efgartigimod PH20 SC treatment to patients with CIDP who are ineligible to participate in a clinical study and have unmet medical need despite available treatment options. The program will continue until the patient discontinues treatment or until the reimbursement process for CIDP concludes, whichever comes first.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Efgartigimod PH20 SC | Subcutaneous administration of Efgartigimod PH20 (via vial or prefilled syringe) |
Timeline
- First posted
- 2021-03-02
- Last updated
- 2026-03-24
Source: ClinicalTrials.gov record NCT04777734. Inclusion in this directory is not an endorsement.